U.S. Markets closed

INSYS Therapeutics, Inc. (INSY)

NasdaqGM - NasdaqGM Delayed Price. Currency in USD
Add to watchlist
9.17-0.11 (-1.19%)
At close: 4:00PM EDT
People also watch

INSYS Therapeutics, Inc.

1333 South Spectrum Boulevard
Suite 100
Chandler, AZ 85286
United States

Full Time Employees423

Key Executives

Mr. Franc Del FosseGen. Counsel and Corp. Sec.307.9kN/A45
Mr. Saeed MotahariPres, CEO & DirectorN/AN/A51
Mr. Andrew G. LongChief Financial OfficerN/AN/AN/A
Mr. Brian JenningsVP of SalesN/AN/AN/A
Mr. Ariyapadi N. KrishnarajVP of Marketing and Managed CareN/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. Its lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS. The company is also developing Cannabidiol Oral Solution, a synthetic cannabidiol for childhood catastrophic epilepsy syndromes; and other product candidates, including other dronabinol line extensions and sublingual spray product candidates. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.

Corporate Governance

INSYS Therapeutics, Inc.’s ISS Governance QualityScore as of August 1, 2017 is 10. The pillar scores are Audit: 10; Board: 6; Shareholder Rights: 10; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.